EGFR and lung cancer: Increasing evidences about the role of DNA methylation in the molecular pathology of lung cancer highlights the need for robust technologies able to establish if whole methylome, and not only methylation changes in single or few genes, could be associated with EGFR-TKI resistance (9, 74).